Walaa Obaid: How Warfarin Went From Poison To Medicine
Walaa Obaid, Former Pharmacist at Oman International Hospita, shared a post on LinkedIn:
”A substance originally developed as a deadly rat poison causing fatal internal bleeding… yet prescribed daily to millions of patients as a life-saving treatment!
Warfarin offers one of the most striking examples in pharmaceutical history that ‘the difference between a lethal toxin and a life-saving medicine lies in a precise understanding of human physiology and meticulously controlled dosing.’
First introduced in the 1940s as a potent rodenticide, clinical research later proved that at precisely calibrated doses, it safely inhibits the vitamin K epoxide reductase enzyme (VKORC1) in the liver. By reducing the synthesis of key clotting factors, it transforms from a rodent poison into a vital defense against:
- Stroke in patients with atrial fibrillation (AFib)
- Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Thromboembolism in patients with mechanical heart valves
Pharmaceutical innovation isn’t always about discovering inherently harmless molecules from day one—it is also about taming dangerous compounds and carefully re-engineering them to guide patients safely away from life-threatening events.
Sources:
1. Journal of Thrombosis and Haemostasis: Historical documentation of Warfarin’s clinical evolution from a rodenticide to a frontline human anticoagulant.
2. U.S. FDA: Official prescribing information and clinical guidelines for Warfarin therapy and target INR monitoring.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden